A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 7, 2015, Pages 392-397

  Cassaday, Ryan D ^a   Goy, Andre ^b   Advani, Suresh ^c   Chawla, Purvi ^d   Nachankar, Rajesh ^d   Gandhi, Mansi ^d   Gopal, Ajay K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^d Piramal Enterprises Limited   (India)

Author keywords

CDK inhibitor; Non Hodgkin lymphoma; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; P 27600; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVONE DERIVATIVE; P276-00;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HERPES ZOSTER; HUMAN; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT PLANNING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; LYMPHOMA, MANTLE-CELL; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLAVONES; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84937521356     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.021     Document Type: Article

References (24)

1. S.A. Pileri, and B. Falini Mantle cell lymphoma Haematologica 94 2009 1488 1492
2. P. Jares, and E. Campo Advances in the understanding of mantle cell lymphoma Br J Haematol 142 2008 149 165
3. P. Jares, E. Campo, M. Pinyol, and et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas: correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity Am J Pathol 148 1996 1591 1600
4. P. Jares, D. Colomer, and E. Campo Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics Nat Rev Cancer 7 2007 750 762
5. P. Martin, and J.P. Leonard Novel therapeutic targets in mantle cell lymphoma Expert Opin Ther Targets 11 2007 929 940
6. K.S. Joshi, M.J. Rathos, R.D. Joshi, and et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00 Mol Cancer Ther 6 2007 918 925
7. 2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models Mol Cancer Ther 6 2007 926 934
8. N.P. Shirsath, S.M. Manohar, and K.S. Joshi P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines Mol Cancer 11 2012 77
9. Hirte H, Digumarti R, Baetz T, et al. A phase I study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms: final report. Paper presented at: 100th AACR Annual Meeting April 18-22, 2009; Denver, CO. Cancer Res, 69, Abstract 3308.
10. B.J. Druker, M. Talpaz, D.J. Resta, and et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
11. G.D. Demetri, M. von Mehren, C.D. Blanke, and et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
12. D.A. Thomas, S. Faderl, J. Cortes, and et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood 103 2004 4396 4407
13. E.L. Kwak, Y.J. Bang, D.R. Camidge, and et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
14. B.D. Cheson, B. Pfistner, M.E. Juweid, and et al. Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
15. E. Camacho, L. Hernandez, S. Hernandez, and et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances Blood 99 2002 238 244
16. M.J. Rathos, K. Joshi, H. Khanwalkar, and et al. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers J Transl Med 10 2012 161
17. D. Subramaniam, G. Periyasamy, S. Ponnurangam, and et al. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis Mol Cancer Ther 11 2012 1598 1608
18. M.J. Rathos, H. Khanwalkar, K. Joshi, and et al. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells BMC Cancer 13 2013 29
19. Clinicaltrials.gov [Web site]. A phase I/II study to evaluate safety and efficacy of P276-00 in combination with gemcitabine in patients with cancer of pancreas (SAVIOR). Available at: http://clinicaltrials.gov/show/NCT00898287. Accessed: September 19, 2013.
20. P.J. Roberts, J.E. Bisi, J.C. Strum, and et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy J Natl Cancer Inst 104 2012 476 487
21. J.P. Leonard, A.S. LaCasce, M.R. Smith, and et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma Blood 119 2012 4597 4607
22. M. Marzec, M. Kasprzycka, R. Lai, and et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity Blood 108 2006 1744 1750
23. C.T. Kouroukis, A. Belch, M. Crump, and et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 1740 1745
24. T.S. Lin, K.A. Blum, D.B. Fischer, and et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders J Clin Oncol 28 2010 418 423